Global Gene Therapies for Cancer Treatment Market Strategic Research Report

Scope of the Report

The global Gene Therapies for Cancer Treatment market size is predicted to grow from US$ 11,290 million in 2025 to US$ 35,710 million in 2032; it is expected to grow at a CAGR of 18.1% from 2026 to 2032.

Cancer gene therapy is an innovative treatment approach that involves directly modifying the patient's genome to treat cancer. Common strategies include Chimeric Antigen Receptor T-cell (CAR-T) therapy, gene editing technologies such as CRISPR-Cas9, and viral vector-mediated gene transduction. Compared to traditional chemotherapy and radiotherapy, gene therapies offer higher specificity and personalized advantages by repairing or replacing oncogenes at the molecular level, activating the immune system to recognize and eliminate tumor cells, or enhancing anti-tumor immune responses. Cancer gene therapies are applicable to various cancer types, including hematologic malignancies (such as leukemia and lymphoma) and solid tumors (such as lung and breast cancer). Although challenges remain, such as high costs, manufacturing complexities, and long-term efficacy, the demonstrated effectiveness in clinical trials positions gene therapy as a significant research direction in oncology.

The cancer gene therapy market is rapidly evolving, driven by several key factors: First, the rising incidence of cancer and the limitations of traditional treatments have increased the demand for novel therapeutic options. Second, advancements in gene editing and cell engineering technologies have made the development and production of cancer gene therapies more feasible. Third, supportive policies from regulatory agencies regarding personalized and precision medicine have created a favorable environment for the clinical application of gene therapies. Fourth, patients' focus on efficacy and quality of life has driven the demand for innovative treatments. Additionally, collaborations between biopharmaceutical companies and research institutions have accelerated the translation of technologies and product development.

Despite the significant potential of cancer gene therapies, several challenges and risks persist. First, the high treatment costs, involving personalized cell processing and gene editing, increase the burden on patients and healthcare systems. Second, the manufacturing process is complex, encompassing cell collection, gene modification, expansion, and reinfusion, with any deviation potentially impacting efficacy and safety. Third, the long-term efficacy and potential side effects are not yet fully understood, requiring more clinical data for validation. Fourth, the regulatory approval processes are cumbersome and time-consuming, potentially delaying the market introduction of new therapies. Fifth, the market is highly competitive, with numerous companies and research institutions investing in R&D, leading to increased risks of technological and product homogeneity.

Downstream demand for cancer gene therapies is exhibiting the following trends: First, with the widespread adoption of precision medicine concepts, there is an increasing demand from patients and healthcare institutions for personalized treatment plans. Second, as efficacy data accumulates, more cancer patients, especially those with refractory or relapsed conditions, are considering gene therapies. Third, insurance companies and payers are gradually expanding coverage for gene therapies, reducing the financial burden on patients. Fourth, patients' concerns about treatment safety and quality of life are prompting research and development to focus more on controlling side effects and optimizing treatment regimens. Additionally, improvements in patient education and information access have enhanced acceptance of new therapies.

This report presents a comprehensive overview of the global Gene Therapies for Cancer Treatment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Viral Vectors
• Non-viral Vectors

Segment by players, this report covers

• Biogen
• Novartis
• Gilead Sciences
• Sarepta Therapeutics
• Sunway Biotech
• SIBIONO
• AnGes
• Orchard Therapeutics
• Human Stem Cells Institute

Segment by Application

• Solid Tumors
• Hematologic Malignancies

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Gene Therapies for Cancer Treatment market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Solid Tumors, Hematologic Malignancies evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact